Crown Bioscience Expands its Life Science Portfolio
(Thomson Reuters ONE) -
SANTA CLARA, Calif., July 13, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a
wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554)
and a global drug discovery and development services company providing
translational platforms to advance oncology, cardiovascular and metabolic
disease research, has released another substantial collection of life science
products to its e-commerce platform.
CrownBio will add a significant number of cell lines and reference standards
related to EGFR, KRAS, and BRAF signaling cascades of the MAPK pathway, which
plays a critical role in the development and progression of cancer. Further
enhancements to the CrownBio catalog also include additional monoclonal
antibodies to immune checkpoint and cancer-related targets, as well as compounds
to activate or inhibit signaling pathways.
This product expansion further strengthens CrownBio's current product offerings
within preclinical drug discovery and cancer research which already includes
antibodies for in vivo and in vitro studies, recombinant proteins, recombinant
cell lines, tumor samples for oncology research and development, and tumor
tissue microarrays.
"The expansion of products validates our commitment to offer a complementary set
of reagents, while further broadening the breath of products available from
CrownBio. Furthermore, we have extended our customer service hours for more
immediate and convenient access to our product support," commented Debby
Saunders, Executive Director of Life Science Development at CrownBio.
"We are very pleased with the growth of the life science division," stated
Laurie Heilmann, SVP of Global Strategy, Marketing and Business Development.
"The division continues to demonstrate significant growth, we remain committed
to providing products that meet our customers need and a method to access them
quickly and easily."
CrownBio's online store can be accessed via: https://www.crownbio.com/shop.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company
providing translational platforms to advance oncology and metabolic disease
research. With an extensive portfolio of relevant models and predictive tools,
Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc. marketing(at)crownbio.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crown Bioscience Inc. via GlobeNewswire
Datum: 13.07.2017 - 14:00 Uhr
Sprache: Deutsch
News-ID 552304
Anzahl Zeichen: 3073
contact information:
Town:
Santa Clara
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 213 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Crown Bioscience Expands its Life Science Portfolio"
steht unter der journalistisch-redaktionellen Verantwortung von
Crown Bioscience Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
